Literature DB >> 9662294

Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy.

K F McGonigle1, S L Shaw, S A Vasilev, T Odom-Maryon, S Roy, J F Simpson.   

Abstract

OBJECTIVE: This study was conducted to examine the histopathologic changes in tamoxifen-treated postmenopausal patients with endometrial thickness > or = 5 mm with transvaginal ultrasonography. STUDY
DESIGN: Thirty-five tamoxifen-treated postmenopausal breast cancer patients underwent transvaginal pelvic ultrasonography with endometrial thickness > or = 5 mm followed by either curettage-hysteroscopy (n = 24), or hysterectomy (n = 11). Endometrial histopathologic findings were examined.
RESULTS: Overall, endometrial polyps were the most common histopathologic finding (23 of 35 patients). Endometrial cystic atrophy was uncommonly detected in patients undergoing curettage-hysteroscopy (1 of 24 patients) compared with patients undergoing hysterectomy (9 of 11 patients). No cases of endometrial cancer or hyperplasia were detected.
CONCLUSIONS: Endometrial polyps were a frequent finding in tamoxifen-treated postmenopausal women who had endometrial thickness > or = 5 mm with the use of transvaginal ultrasonography. Endometrial cystic atrophy may explain "thickened endometrium" on transvaginal ultrasonography in this patient population with no evidence of endometrial polyps, hyperplasia, or adenocarcinoma after surgical evaluation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9662294     DOI: 10.1016/s0002-9378(98)70315-1

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

1.  Gynaecological effects of tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

Review 2.  Antiestrogens--tamoxifen, SERMs and beyond.

Authors:  K Dhingra
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

3.  Investigation of women with postmenopausal uterine bleeding: clinical practice recommendations.

Authors:  Malcolm G Munro
Journal:  Perm J       Date:  2013-12-30

Review 4.  Guidelines for monitoring patients taking tamoxifen treatment.

Authors:  P Neven; H Vernaeve
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.228

5.  Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women.

Authors:  M B Marttunen; B Cacciatore; P Hietanen; S Pyrhönen; A Tiitinen; T Wahlström; O Ylikorkala
Journal:  Br J Cancer       Date:  2001-04-06       Impact factor: 7.640

Review 6.  The effect of tamoxifen on the genital tract.

Authors:  Sandra A Polin; Susan M Ascher
Journal:  Cancer Imaging       Date:  2008-06-30       Impact factor: 3.909

7.  Endometrial safety of ospemifene: results of the phase 2/3 clinical development program.

Authors:  Ginger D Constantine; Steven R Goldstein; David F Archer
Journal:  Menopause       Date:  2015-01       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.